2 min read
Federal Minister for Finance and Revenue, Senator Muhammad Aurangzeb, met with a high-level delegation from the Pharma Bureau today to discuss pressing issues affecting Pakistan’s pharmaceutical sector. The meeting focused on policy, regulatory, and economic concerns, and highlighted ways to strengthen the industry’s role in public health and economic growth.
The delegation was led by Pharma Bureau Chairman Syed Anis Ahmed and included Co-chair Erum Shakir Rahim, CEOs of leading pharmaceutical firms Haleon Pakistan and Roche Pakistan, as well as other senior executives.
During discussions, the Pharma Bureau presented an overview of the sector’s recent performance, noting improvements in regulatory processes, greater digitalization, and enhanced engagement between regulators and industry stakeholders. The delegation also highlighted progress toward achieving higher World Health Organization maturity levels for the national drug regulator, along with developments in product approvals, exports, and broader macroeconomic conditions.
Industry representatives also raised operational concerns, including challenges related to pricing, product availability, regulatory processes, investment facilitation, taxation, innovation, and export potential. They stressed the need for consistent policies, strong governance, and measures to safeguard patient interests, while further enhancing regulatory standards in line with international norms.
Senator Aurangzeb acknowledged the sector’s critical contribution to public health, employment, and overall economic activity. He briefed participants on the government’s broader economic reform agenda, including steps to stabilize the macroeconomy, rationalize the tax system, expand documentation, and promote growth across all sectors.
The Minister assured the delegation that their concerns and proposals would be reviewed carefully in coordination with relevant ministries and regulatory bodies. He emphasized the government’s commitment to regular stakeholder engagement and facilitating the industry within the framework of national priorities and fiscal sustainability.
The meeting ended on a positive note, with both sides agreeing to maintain dialogue and cooperation to address challenges, encourage innovation, and strengthen the pharmaceutical sector’s continued growth and contribution to the economy.
